| URL | https://www.forbes.com/sites/stevebanker/2025/07/2 |
| Source | Forbes |
| Date Published | 07/23/2025 |
| Author Name | Steve Banker |
| Company/Division name | Merck Animal Health |
| Parent company | Merck KGaA |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2025 |
| Year reshoring implemented or to be implemented: | 2028 |
| Capital investment ($): | 9,000 |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | biopharmaceuticals |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Impact on domestic economy, Infrastructure, Proximity to customers/market |